This innovative peptide targets GLP-1, GIP, and glucagon receptors , helping reduce cravings, enhance fat metabolism, and improve overall energy regulation
Archived from the original on March 8, 2022
The landmark cardiovascular outcome trials that led to expanded indications for several GLP-1 drugs provide the most robust safety data available
The STEP 1 trial (Wilding et al., NEJM 2021) demonstrated an average 14.9% body weight reduction with semaglutide 2.4mg weekly over 68 weeks, compared to 2.4% with placebo a magnitude of effect that no prior anti-obesity medication had achieved
This occurs when a larger proportion of hair follicles shift from the active growth phase into the resting phase, resulting in increased shedding several months later
Supplementing with NAD+ AT HOME can help replenish these vital levels, enhancing cellular health and vitality